Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum94786ArticlesСтатьиReview ArticleThe prolonged regime: contraceptive and non-contraceptive benefitsПролонгированный режим: контрацептивные и неконтрацептивные преимуществаKarakhalisL. YuКарахалисЛ. Ю

д-р мед. наук, проф., проф. каф. акушерства, гинекологии и перинатологии ФПК и ППС ФГБОУ ВО КубГМУ

lomela@mail.ruKuban State Medical University of the Ministry of Health of the Russian FederationФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России15062017196VOL 19, NO6 (2017)ТОМ 19, №6 (2017)545628122021Copyright ©; 2017, Consilium MedicumCopyright ©; 2017, ООО "Консилиум Медикум"2017Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/94786

The article concerns the prolonged use of contraception which has a lot of benefits compared to traditional use of oral contraception as it lowers the menstruation frequency, the risk of menstruation symptoms development, endometriosis and severe dysmenorrhea frequency by ceasing the endogenous estradiol production and providing highly effective, safe and reversal contraception. The article focuses on prolonged use of levonorgestrelcontaining hormonal contraceptive. Levonorgestrel increases the safety and tolerability of hormonal contraception.

В статье рассматриваются пролонгированные режимы контрацепции, имеющие неоспоримые преимущества перед традиционными формами оральной контрацепции: снижая число менструаций, сокращают риск распространенных менструальных симптомов, частоту эндометриоза или тяжелой дисменореи, предотвращая эндогенную продукцию эстрадиола и в то же время обеспечивая высокоэффективную, безопасную контрацепцию и быструю ее обратимость. В данной статье взгляд фокусируется на долгосрочном использовании левоноргестрелсодержащего комбинированного гормонального контрацептива. Свойства левоноргестрела повышают безопасность и переносимость гормональной контрацепции.

hormonal contraceptionprolonged regimeгормональная контрацепцияпролонгированный режимSchlaff W.D, Lynch A.M, Hughes H.D et al. Manipulation of the pill - free interval in oral contraceptive pill users: the effects on follicular suppression. Am J Obstet Gynecol 2004; 190: 943-51.Sulak P.J, Scow R.D, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261-6.Coffee A, Kuehl T.K, Willis S.A, Sulak P.J. Oral contraceptives and premenstrualsymptoms: comparisonof a 21/7 and extendedregimen. Am J Obstet Gynecol 2006; 195: 1311-9.Vandever M.A, Kuehl T.J, Sulak P.J et al. Evaluation ofpituitary - ovarian axis suppression withthree oral contraceptive regimens. Contraception 2008; 77 (3): 162-70.Edelman A.B, Gallo M.F, Jensen J.T et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005; 3: CD004695.Yonkers K.A, Brown C, Pearlstein T.B et al. Efficacy of a new low dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol 2005; 106: 492-501.Archer D.F, Jensen J.T, Johnson J.V et al. Evaluation of a continuous regimen of levonorgestrel/ethinylestradiol: phase 3 studyresults. Contraception 2006; 74 (6): 439-45.Davis A.R, Kroll R, Soltes B et al. Return to menses after continuous use of a low - dose oral contraceptive. Obstet Gynecol 2006; 107: 3S.Den Tonkelaar I, Oddens B.J. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use, and hormone replacement therapy use. Contraception 1999; 59: 357-62.Andrist L/C, Arias R/D, Nucatola D et al. Women’s and providers’ attitudes toward menstrual suppression with extended use of oral contraceptives. Contraception 2004; 70: 359-63.Glasier A.F, Smith K.B, van der Spuy Z.M et al. Amenorrhea associated with contraception - an international study on acceptability. Contraception 2003; 67: 1-8.Sulak P.J, Cressman B.E, Waldrop E et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179-83.Sulak P.J, Kuehl T.J, Ortiz M, Shull B.L. Acceptance of altering the standard 21 - day/7 - day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186: 1142-9.Shakespeare J, Neve E, Hodder K. Is norethisterone a lifestyle drug? Results of database analysis. BMJ 2000; 320: 291.Anderson F.D, Hait H the Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89-96.Miller L, Hughes J.P. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol 2003; 101: 653-61.Аrcher D.F, Kovalevsky G, Ballagh S, Grubb G.S. Effect on ovarian activity of a continuous - use regimen of oral levonorgestrel/ethinyl estradiol. Fertil Steril 2005; 84 (Suppl.): S24.Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 microg) and ethinyl estradiol (15 microg) on ovarian activity. Fertil Steril 1999; 72 (1): 115-20.Spona J, Elstein M, Feichtinger W et al. Shorter pill - freeinterval in combined oral contraceptives decreases follicular development. Contraception 1996; 54 (2): 71-7.Trussell J. Contraceptive efficacy. In: Hatcher R.A, Trussell J, Nelson A.L et al, editors. Contraceptive Technology, 19th revisededition. New York NY: Ardent Media, 2007; p. 747-56.Shrader S.P, Dickerson L.M. Extended - and Continuous - Cycle Oral Contraceptives. Pharmacotherapy 2008; 28 (8): 1033-40.Walker A.M. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 1998; 57 (3): 169-81.Hennessy S, Berlin J.A, Kinman J.L et al. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta - analysis and formal sensitivity analysis. Contraception 2001; 64 (2): 125-33.Kemmeren J.M, Algra A, Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: meta - analysis. BMJ 2001; 323 (7305): 131-4.Jick S, Hernandez. Risk of non - fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel case - control study using United States claims data. BMJ 2011; 342: d2151.Parkin, Sharples, Hernandez, Jick. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case - control study based on UK General Practice Research Database. BMJ 2011; 342: d2139.Lidegaard O. Maturitas 2013; 74: 1-2.Vinogradova Y et al. BMJ 2015; 350: h2135.ACOG Committee on Practice Bulletins - Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women withcoexisting medical conditions. Obstet Gynecol 2006; 107 (6): 1453-72.Department of Reproductive Health, World Health Organization. Medical Eligibility Criteria for Contraceptive Use. 4th ed. 2009. http://www.who. int/reproductivehealth /publications/family_planning/9789241563888/en/index.htmlKaunitz A. Hormonal Contraception in Women of Older Reproductive Age. N Engl J Med 2008; 358: 1262-70.Sidney S, Siscovick D.S, Petitti D.B et al. Myocardial infarction and use of low - dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998; 98: 1058-63.Schwartz S.M, Petitti D.B, Siscovick D.S et al. Stroke and use of low - dose oral contraceptives in young women: a pooled analysis of two US studies. Stroke 1998; 29: 2277-84.Cardoso F, Polonia J, Santos A et al. Low - dose oral contraceptives and 24-hour ambulatory blood pressure. Int J Gynaecol Obstet 1997; 59: 237-43.Petitti D.B. Clinical practice. Combinationestrogen - progestin oral contraceptives [published correction appears in N Engl J Med 2004; 350 (1): 92]. N Engl J Med 2003; 349 (15): 1443-50.Gold R. Rekindling efforts to prevent unplanned pregnancy: A matter of “equity and common sense”. Guttmacher Policy Rev 2006; 9: 2-6.Davis S.R, Bitzer J, Giraldi A et al. Change to either a nonandrogenic or androgenic progestin - containing oral contraceptive preparation s associated with improved sexual function in women with oral contraceptive - associated sexual dysfunction. J Sex Med 2013; 10 (12): 3069-79.Nappi R.E, Davis S.R, Parke S et al. Effects of Estradiol Valerate/Dienogest Compared with Ethinyl Estradiol/Levonorgestrel on Libido. Endocr Rev; 32 (03_MeetingAbstracts): P1-315.Munro M.G, Critchley H.O, Broder M.S et al. FIGO classification system (PALM COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet 2011; 113: 3-13.Krishnan S, Kiley J. The lowest - dose, extended - cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 mg/levonorgestrel 100 mg + ethinyl estradiol 10 mg. Int J Women’s Health 2010; 2: 235-9.